Non-Hodgkin’s Lymphoma

Since its inception, one of the Company’s key areas of focus has been Non-Hodgkin’s Lymphoma (NHL).  Diffuse Large B-Cell Lymphoma is the most common form of NHL and drug resistance is a serious obstacle for these patients.  Very often, an NHL patient’s treatment begins with R-CHOP therapy, a multi-agent chemotherapy program.  It is estimated that, over time, approximately 40% of these patients will become resistant to R-CHOP and require second-line therapy.  One of the most recent developments in second-line therapy is the multidrug therapy known as RICE.

Several in vitro experiments have shown that Rescue’s base compound and RTI-79, our lead drug candidate, enhance the efficacy of individual R-CHOP and RICE therapy components.  The results indicate that Rescue’s compound may be an effective additive to first-line therapy because the Company has seen synergy with R-CHOP components such as doxorubicin and vincristine.  In the second-line treatment environment, Rescue has seen a synergistic effect with the Etoposide component of the RICE therapy routine.

The results of these experiments have been confirmed in multiple mouse models where tumor growth is materially suppressed when RTI-79 is administered along with doxorubicin.   The graph below is representative of the in vivo results seen to date.

G3 cells were implanted in mice and allowed to develop into tumor nodules prior to treatment with CHOP or CHOP plus the Rescue Base Compound (precursor to RTI-79). The G3 cell line is a CHOP-resistant line of NHL cells derived from the CRL2631 NHL cell line. Twelve days after the beginning of treatment, Tumor Burden, as measured by tumor volume (mm3), was 80% less in mice treated with CHOP plus the Base Compound when compared to those treated with treated with CHOP alone.

G3 cells were implanted in mice and allowed to develop into tumor nodules prior to treatment with CHOP or CHOP plus the Rescue Base Compound (precursor to RTI-79). The G3 cell line is a CHOP-resistant line of NHL cells derived from the CRL2631 NHL cell line. Twelve days after the beginning of treatment, Tumor Burden, as measured by tumor volume (mm3), was 80% less in mice treated with CHOP plus the Base Compound when compared to those treated with treated with CHOP alone.

After confirmation of safety in its first Phase I clinical trial, the Company plans to conduct human trials for NHL.